MiMedx Group, Inc (NASDAQ: MDXG - Get Free Report) has been assigned an average recommendation of "M

Compugen (NASDAQ: CGEN - Get Free Report) and MiMedx Group (NASDAQ: MDXG - Get Free Report) are both

MiMedx Group (NASDAQ: MDXG - Get Free Report) and Protagonist Therapeutics (NASDAQ: PTGX - Get Free

MiMedx Group, Inc. (Nasdaq: MDXG) ("MIMEDX" or the "Company") today announced that t

Court Vacates FDA Determinations That AXIOFILL Is Not Minimally Manipulated and Should Be Classified

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr.,

MARIETTA, Ga., Sept. 08, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the

Deutsche Bank AG bought a new position in shares of MiMedx Group, Inc (NASDAQ: MDXG) in the second q

Craig-Hallum analyst Chase Knickerbocker maintains MiMedx Group (NASDAQ:MDXG) with a Buy and rais

Cantor Fitzgerald analyst Sarah James reiterates MiMedx Group (NASDAQ:MDXG) with a Overweight and

NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti,

U.S. stock futures rise, Meta shares drop 9.4%, Teladoc Health and Rentokil Initial fall after mixed

MiMedx Group, Inc. (MDXG) Q2 2026 Earnings Call Transcript

MiMedx Group NASDAQ: MDXG said it has agreed to acquire Sanara MedTech in a transaction valued at $3

MiMedx Group (NASDAQ:MDXG) affirms FY2026 sales outlook from $260.000 million-$290.000 million to $2

MiMedx Group (NASDAQ:MDXG) reported quarterly losses of $(0.05) per share which met the analyst cons

Reports  Second Quarter Net Sales of $64 Million Reiterates Full Year Financial Outlook on a Standal

Transformational Combination Creates a Leading Regenerative Medicine Company Across Numerous Surgica

Transformational Combination Creates a Leading Regenerative Medicine Company Across Numerous Surgica

MARIETTA, Ga., July 20, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the

NEW YORK, May 21, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors

MARIETTA, Ga., May 21, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “

NEW YORK, May 19, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of invest

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of MiMedx Group, Inc.

NEW YORK, May 14, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors

NEW YORK, May 12, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of invest

Investors need to pay close attention to MDXG stock based on the movements in the options market lat

Citizens analyst David Turkaly maintains MiMedx Group (NASDAQ:MDXG) with a Market Outperform and

MiMedx Group (NASDAQ:MDXG) reported quarterly losses of $(0.05) per share which missed the analyst c

MiMedx Group (NASDAQ:MDXG) lowers FY2026 sales outlook from $340.000 million-$360.000 million to $26

Citizens analyst David Turkaly maintains MiMedx Group (NASDAQ:MDXG) with a Market Outperform and

Craig-Hallum analyst Chase Knickerbocker maintains MiMedx Group (NASDAQ:MDXG) with a Buy and lowe

MiMedx Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company") today announced the com

MiMedx Group (NASDAQ:MDXG) sees FY2026 sales of $340.000 million-$360.000 million vs $376.533 millio

MiMedx Group (NASDAQ:MDXG) reported quarterly earnings of $0.14 per share which beat the analyst con

Citizens analyst David Turkaly initiates coverage on MiMedx Group (NASDAQ:MDXG) with a Market Out

Cantor Fitzgerald analyst Sarah James maintains MiMedx Group (NASDAQ:MDXG) with a Overweight and

MiMedx Group, Inc. (Nasdaq: MDXG) ("MIMEDX" or the "Company") today announced it has

Lake Street analyst Brooks O'Neil maintains MiMedx Group (NASDAQ:MDXG) with a Buy and lowers